View in EDS HTML Full Text PDF Full Text

Lacosamide monotherapy in clinical practice: A retrospective chart review.

Saved in:
Bibliographic Details
Title: Lacosamide monotherapy in clinical practice: A retrospective chart review.
Authors: Villanueva, V., Giráldez, B. G., Toledo, M., De Haan, G. J., Cumbo, E., Gambardella, A., De Backer, M., Joeres, L., Brunnert, M., Dedeken, P., Serratosa, J.
Source: Acta Neurologica Scandinavica. Sep2018, Vol. 138 Issue 3, p186-194. 9p.
Subjects: Vimpat, Drug efficacy, Partial epilepsy, Medical practice, Retrospective studies, Drug tolerance, Therapeutics
Abstract: Objective: To assess effectiveness and tolerability of first‐line and conversion to lacosamide monotherapy for focal seizures. Materials and Methods: Retrospective, non‐interventional chart review of lacosamide monotherapy patients aged ≥16 years in Europe. Outcomes included retention rate at observational point (OP) 3 (12 ± 3 months), seizure freedom rates at OP2 (6 ± 3 months) and OP3 and adverse drug reactions (ADRs). Results: A total of 439 patients were included (98 first‐line and 341 conversion to monotherapy; 128 aged ≥65 years [25 first‐line and 103 conversion to monotherapy]). First‐line and conversion to monotherapy retention rates were 60.2% (59/98; 95% confidence interval [CI] 49.8%‐70.0%) and 62.5% (213/341; 57.1%‐67.6%), respectively. Kaplan‐Meier estimates of 12‐month retention rates were 81.2% and 91.4% for first‐line and conversion to monotherapy, respectively. First‐line and conversion to monotherapy retention rates in patients aged ≥65 years were 60.0% (38.7%‐78.9%) and 68.9% (59.1%‐77.7%), respectively. At OP2, 66.3% of first‐line and 63.0% of conversion to monotherapy patients were seizure free. At OP3, 60.2% of first‐line and 52.5% of conversion to monotherapy patients were seizure free. In the ≥65 years subgroup, seizure freedom rates at OP2 were 72.0% and 68.0% for first‐line and converted to monotherapy, respectively, and at OP3, 68.0% and 56.3%, respectively. Overall, 52 of 439 (11.8%) patients reported ADRs (16.4% in ≥65 years subgroup), most commonly dizziness (5.0%), headache (2.1%) and somnolence (1.6%). Conclusions: Lacosamide was effective and well tolerated as first‐line or conversion to monotherapy in a clinical setting in adult and elderly patients with focal seizures. [ABSTRACT FROM AUTHOR]
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 131169920
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lacosamide monotherapy in clinical practice: A retrospective chart review.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Villanueva%2C+V%2E%22">Villanueva, V.</searchLink><br /><searchLink fieldCode="AR" term="%22Giráldez%2C+B%2E+G%2E%22">Giráldez, B. G.</searchLink><br /><searchLink fieldCode="AR" term="%22Toledo%2C+M%2E%22">Toledo, M.</searchLink><br /><searchLink fieldCode="AR" term="%22De+Haan%2C+G%2E+J%2E%22">De Haan, G. J.</searchLink><br /><searchLink fieldCode="AR" term="%22Cumbo%2C+E%2E%22">Cumbo, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Gambardella%2C+A%2E%22">Gambardella, A.</searchLink><br /><searchLink fieldCode="AR" term="%22De+Backer%2C+M%2E%22">De Backer, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Joeres%2C+L%2E%22">Joeres, L.</searchLink><br /><searchLink fieldCode="AR" term="%22Brunnert%2C+M%2E%22">Brunnert, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Dedeken%2C+P%2E%22">Dedeken, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Serratosa%2C+J%2E%22">Serratosa, J.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Acta+Neurologica+Scandinavica%22">Acta Neurologica Scandinavica</searchLink>. Sep2018, Vol. 138 Issue 3, p186-194. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Vimpat%22">Vimpat</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+efficacy%22">Drug efficacy</searchLink><br /><searchLink fieldCode="DE" term="%22Partial+epilepsy%22">Partial epilepsy</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+practice%22">Medical practice</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+studies%22">Retrospective studies</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+tolerance%22">Drug tolerance</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: To assess effectiveness and tolerability of first‐line and conversion to lacosamide monotherapy for focal seizures. Materials and Methods: Retrospective, non‐interventional chart review of lacosamide monotherapy patients aged ≥16 years in Europe. Outcomes included retention rate at observational point (OP) 3 (12 ± 3 months), seizure freedom rates at OP2 (6 ± 3 months) and OP3 and adverse drug reactions (ADRs). Results: A total of 439 patients were included (98 first‐line and 341 conversion to monotherapy; 128 aged ≥65 years [25 first‐line and 103 conversion to monotherapy]). First‐line and conversion to monotherapy retention rates were 60.2% (59/98; 95% confidence interval [CI] 49.8%‐70.0%) and 62.5% (213/341; 57.1%‐67.6%), respectively. Kaplan‐Meier estimates of 12‐month retention rates were 81.2% and 91.4% for first‐line and conversion to monotherapy, respectively. First‐line and conversion to monotherapy retention rates in patients aged ≥65 years were 60.0% (38.7%‐78.9%) and 68.9% (59.1%‐77.7%), respectively. At OP2, 66.3% of first‐line and 63.0% of conversion to monotherapy patients were seizure free. At OP3, 60.2% of first‐line and 52.5% of conversion to monotherapy patients were seizure free. In the ≥65 years subgroup, seizure freedom rates at OP2 were 72.0% and 68.0% for first‐line and converted to monotherapy, respectively, and at OP3, 68.0% and 56.3%, respectively. Overall, 52 of 439 (11.8%) patients reported ADRs (16.4% in ≥65 years subgroup), most commonly dizziness (5.0%), headache (2.1%) and somnolence (1.6%). Conclusions: Lacosamide was effective and well tolerated as first‐line or conversion to monotherapy in a clinical setting in adult and elderly patients with focal seizures. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=131169920
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ane.12920
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 186
    Subjects:
      – SubjectFull: Vimpat
        Type: general
      – SubjectFull: Drug efficacy
        Type: general
      – SubjectFull: Partial epilepsy
        Type: general
      – SubjectFull: Medical practice
        Type: general
      – SubjectFull: Retrospective studies
        Type: general
      – SubjectFull: Drug tolerance
        Type: general
      – SubjectFull: Therapeutics
        Type: general
    Titles:
      – TitleFull: Lacosamide monotherapy in clinical practice: A retrospective chart review.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Villanueva, V.
      – PersonEntity:
          Name:
            NameFull: Giráldez, B. G.
      – PersonEntity:
          Name:
            NameFull: Toledo, M.
      – PersonEntity:
          Name:
            NameFull: De Haan, G. J.
      – PersonEntity:
          Name:
            NameFull: Cumbo, E.
      – PersonEntity:
          Name:
            NameFull: Gambardella, A.
      – PersonEntity:
          Name:
            NameFull: De Backer, M.
      – PersonEntity:
          Name:
            NameFull: Joeres, L.
      – PersonEntity:
          Name:
            NameFull: Brunnert, M.
      – PersonEntity:
          Name:
            NameFull: Dedeken, P.
      – PersonEntity:
          Name:
            NameFull: Serratosa, J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: Sep2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 00016314
          Numbering:
            – Type: volume
              Value: 138
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Acta Neurologica Scandinavica
              Type: main
ResultId 1